JP2013522239A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522239A5 JP2013522239A5 JP2012557295A JP2012557295A JP2013522239A5 JP 2013522239 A5 JP2013522239 A5 JP 2013522239A5 JP 2012557295 A JP2012557295 A JP 2012557295A JP 2012557295 A JP2012557295 A JP 2012557295A JP 2013522239 A5 JP2013522239 A5 JP 2013522239A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- formulation
- solvent system
- api
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 35
- 238000009472 formulation Methods 0.000 claims description 27
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 150000002772 monosaccharides Chemical group 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 claims description 8
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 8
- TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 claims description 8
- 150000004676 glycans Chemical class 0.000 claims description 7
- 229920001282 polysaccharide Polymers 0.000 claims description 7
- 239000005017 polysaccharide Substances 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 239000012298 atmosphere Substances 0.000 claims description 6
- 229920002988 biodegradable polymer Polymers 0.000 claims description 6
- 239000004621 biodegradable polymer Substances 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 229920002774 Maltodextrin Polymers 0.000 claims description 4
- 239000005913 Maltodextrin Substances 0.000 claims description 4
- 108091006006 PEGylated Proteins Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229960002903 benzyl benzoate Drugs 0.000 claims description 4
- 239000003114 blood coagulation factor Substances 0.000 claims description 4
- 229940019700 blood coagulation factors Drugs 0.000 claims description 4
- -1 glycofural Chemical compound 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 239000005556 hormone Substances 0.000 claims description 4
- 229940088597 hormone Drugs 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 125000005647 linker group Chemical group 0.000 claims description 4
- 229940035034 maltodextrin Drugs 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 239000003124 biologic agent Substances 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
- 150000005690 diesters Chemical class 0.000 claims description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920002521 macromolecule Polymers 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 150000003384 small molecules Chemical class 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001600 hydrophobic polymer Polymers 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31366610P | 2010-03-12 | 2010-03-12 | |
| US61/313,666 | 2010-03-12 | ||
| PCT/US2011/028195 WO2011112996A2 (en) | 2010-03-12 | 2011-03-11 | Injectable drug delivery system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522239A JP2013522239A (ja) | 2013-06-13 |
| JP2013522239A5 true JP2013522239A5 (enExample) | 2014-04-24 |
Family
ID=44148866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557295A Pending JP2013522239A (ja) | 2010-03-12 | 2011-03-11 | 注射用薬物送達システム |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110229457A1 (enExample) |
| EP (1) | EP2544658A2 (enExample) |
| JP (1) | JP2013522239A (enExample) |
| CA (1) | CA2792771A1 (enExample) |
| WO (1) | WO2011112996A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3613413A1 (en) * | 2011-12-05 | 2020-02-26 | Incept, LLC | Medical organogel processes and compositions |
| AU2013355043A1 (en) * | 2012-12-06 | 2015-07-02 | Tobira Therapeutics, Inc. | Oligonucleotide formulation |
| CN106573133B (zh) | 2014-08-19 | 2020-03-03 | 加利福尼亚大学董事会 | 用于局部药物递送的植入物及其使用方法 |
| US20180371158A1 (en) * | 2015-12-18 | 2018-12-27 | Abraham Joy | Peptidomimetic polymers as controlled release matrices for small molecules, biologicals, synthetic or semi-synthetic macromolecules |
| JP7054793B2 (ja) * | 2017-07-07 | 2022-04-15 | パナソニックＩｐマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
| JP6952279B2 (ja) * | 2017-07-07 | 2021-10-20 | パナソニックＩｐマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
| JP7054792B2 (ja) * | 2017-07-07 | 2022-04-15 | パナソニックＩｐマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
| CN110537098B (zh) * | 2017-07-07 | 2022-01-25 | 松下知识产权经营株式会社 | 信息提供方法、信息处理系统、信息终端及信息处理方法 |
| JP6924969B2 (ja) * | 2017-07-07 | 2021-08-25 | パナソニックＩｐマネジメント株式会社 | 情報提供方法、情報処理システム、情報端末、及び情報処理方法 |
| JP7487220B2 (ja) * | 2019-03-05 | 2024-05-20 | ダウ グローバル テクノロジーズ エルエルシー | カスパーゼ活性を誘導するためのポリエチレングリコール誘導体 |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11338119B2 (en) | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| CN111956638B (zh) * | 2020-08-06 | 2023-01-24 | 上海宛文创业孵化器管理合伙企业(有限合伙) | 蓓萨罗丁或/和其药学上可接受的盐在制备抗肺动脉高压药物中的应用 |
| WO2023056447A1 (en) | 2021-10-01 | 2023-04-06 | Promega Corporation | Compounds and methods for detection of nitric oxide |
| CN116870238A (zh) * | 2023-08-25 | 2023-10-13 | 中国海洋大学 | 一种抑菌介孔淀粉止血粉及其制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4433101A1 (de) * | 1994-09-16 | 1996-03-21 | Bauer Kurt Heinz Prof Dr | Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren |
| AU739469B2 (en) * | 1996-12-20 | 2001-10-11 | Alza Corporation | Gel composition and methods |
| US6224893B1 (en) * | 1997-04-11 | 2001-05-01 | Massachusetts Institute Of Technology | Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering |
| US6472512B1 (en) * | 1998-07-21 | 2002-10-29 | Human Genome Sciences, Inc. | Keratinocyte derived interferon |
| EP1481695A1 (en) * | 1999-10-15 | 2004-12-01 | Genetics Institute, LLC | Formulations of hyaluronic acid for delivery of osteogenic proteins |
| US6703040B2 (en) | 2000-01-11 | 2004-03-09 | Intralytix, Inc. | Polymer blends as biodegradable matrices for preparing biocomposites |
| CA2494241C (en) * | 2000-02-08 | 2011-06-14 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| JP2004511431A (ja) * | 2000-06-28 | 2004-04-15 | アトゥル・ジェイ・シュクラ | 生物活性物質を含む生分解性ビヒクルおよび送達システム |
| JP4817088B2 (ja) * | 2000-10-10 | 2011-11-16 | 株式会社林原生物化学研究所 | 塞栓材料 |
| IL159048A0 (en) * | 2001-06-21 | 2004-05-12 | Genentech Inc | Sustained release formulation |
| JP4624678B2 (ja) * | 2002-02-21 | 2011-02-02 | パイオニア・サージカル・オーソバイオロジックス，インコーポレイテッド | 架橋生物活性ヒドロゲルマトリックス |
| EP1555278A1 (en) | 2004-01-15 | 2005-07-20 | Innocore Technologies B.V. | Biodegradable multi-block co-polymers |
| DE102004021240B4 (de) * | 2004-04-30 | 2008-07-31 | Infineon Technologies Ag | Verfahren zur Herstellung einer Halbleiter-Schaltungsanordnung in BiCMOS-Technologie |
| GB0412866D0 (en) * | 2004-06-09 | 2004-07-14 | Novartis Ag | Organic compounds |
| US20090092650A1 (en) * | 2004-12-15 | 2009-04-09 | Warren Stephen L | Sustained Delivery Formulations of Octreotide Compounds |
| CA2645324A1 (en) | 2006-03-15 | 2007-09-27 | Surmodics, Inc. | Hydrophobic derivatives of natural biodegradable polysaccharides and uses thereof |
| US20090022805A1 (en) * | 2007-06-28 | 2009-01-22 | Joram Slager | Polypeptide microparticles having sustained release characteristics, methods and uses |
| WO2010141553A1 (en) * | 2009-06-02 | 2010-12-09 | Surmodics, Inc. | SILANE-FUNCTIONALIZED HYDROPHOBIC a(1→4)GLUCOPYRANOSE POLYMERS AND POLYMERIC MATRICES FOR IMPLANTATION OR INJECTION |
-
2011
- 2011-03-11 WO PCT/US2011/028195 patent/WO2011112996A2/en not_active Ceased
- 2011-03-11 CA CA2792771A patent/CA2792771A1/en not_active Abandoned
- 2011-03-11 US US13/046,547 patent/US20110229457A1/en not_active Abandoned
- 2011-03-11 EP EP11710949A patent/EP2544658A2/en not_active Withdrawn
- 2011-03-11 JP JP2012557295A patent/JP2013522239A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522239A5 (enExample) | ||
| Yang et al. | Integration of human umbilical cord mesenchymal stem cells-derived exosomes with hydroxyapatite-embedded hyaluronic acid-alginate hydrogel for bone regeneration | |
| US20230414769A1 (en) | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | |
| Hamid Akash et al. | Natural and synthetic polymers as drug carriers for delivery of therapeutic proteins | |
| WO2008136536A1 (ja) | 化学架橋ヒアルロン酸誘導体を含むハイブリッドゲルおよびそれを用いた医薬組成物 | |
| JP2013522239A (ja) | 注射用薬物送達システム | |
| Matricardi et al. | Polysaccharide hydrogels: Characterization and biomedical applications | |
| JP2014514275A5 (enExample) | ||
| JP2010534708A (ja) | 両親媒性ポリマーとｂｍｐファミリーに属する骨形成タンパク質との複合体 | |
| JP2013525414A5 (enExample) | ||
| CA2797058A1 (en) | Conjugated blood coagulation factor viii | |
| Cheng et al. | Delivery of a granzyme B inhibitor gene using carbamate-mannose modified PEI protects against cytotoxic lymphocyte killing | |
| CA3216091A1 (en) | Oral delivery of oligonucleotides | |
| Li et al. | Structural design and physicochemical foundations of hydrogels for biomedical applications | |
| US9644039B2 (en) | Acid-degradable and bioerodible modified polyhydroxylated materials | |
| Lin et al. | Biodegradable micelles from a hyaluronan-poly (ε-caprolactone) graft copolymer as nanocarriers for fibroblast growth factor 1 | |
| US20250032478A1 (en) | Solid forms of resiquimod and formulations thereof | |
| Clapacs | Nanoengineered Constructs for Immunomodulatory Therapeutic Delivery | |
| CN117545509A (zh) | 寡核苷酸的口服递送 | |
| Hernandez-Patlan et al. | Green Biopolymers as Carriers for Innovative Drug Delivery | |
| HK1246333B (zh) | 制备具有优异的肽和蛋白结合性质的接枝共聚物赋形剂的方法 | |
| HK1206378B (en) | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo |